Endo, Inc. presented groundbreaking research on plantar fibromatosis (PFI) and plantar fasciitis (PFA) at the American Podiatric Medical Association Annual Meeting. The company shared findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum (CCH) in patients with PFA and PFI, along with a retrospective analysis of insights from patients with PFI.
These studies aim to develop a potential nonsurgical treatment option for patients suffering from PFI, highlighting Endo’s commitment to improving patient care. The presentations revealed promising results, showing improvements in pain, nodule hardness, and overall condition in patients treated with CCH. Participants expressed a strong interest in nonsurgical options like CCH, emphasizing the need for therapies that reduce or halt nodule growth in PFI. Endo’s research signifies a significant step forward in addressing the challenges posed by PFI and PFA, offering hope for improved treatment options for individuals affected by these conditions.
Read more from prnewswire.co.uk